References
- Ananthakrishnan R, Gona P. (2010). Pharmacological modeling and biostatistical analysis of a new drug. Open Access J Clin Trials 2:59–82
- Baek IH, Chae JW, Song GY, Kwon KI. (2009). LC-MS/MS assay validation for a new immune modulator, JHL45, and its major metabolite in plasma: application to pharmacokinetic studies in rats. Bull Korean Chem Soc 30:2631–6
- Hanawa K, Hanawa T, Tsuchiya C, et al. (2010). Development of sarpogrelate external preparation for intractable pain control. I. Pre-formulation study on application of modified beta-cyclodextrins. Chem Pharm Bull 58:45–50
- Hara H, Kitajima A, Shimada H, Tamao Y. (1991a). Antithrombotic effect of MCI-9042, a new antiplatelet agent on experimental thrombosis models. Thromb Haemost 66:484–8
- Hara H, Osakabe M, Kitajima A, et al. (1991b). MCI-9042, a new antiplatelet agent is a selective S2-serotonergic receptor antagonist. Thromb Haemost 65:415–20
- Lentz KA. (2008). Current methods for predicting human food effect. AAPS J 10:282–8
- Lentz KA, Quitko M, Morgan DG, et al. (2007). Development and validation of a preclinical food effect model. J Pharm Sci 96:459–72
- Nagatomo T, Rashid M, Abul Muntasir H, Komiyama T. (2004). Functions of 5-HT2A receptor and its antagonists in the cardiovascular system. Pharmacol Ther 104:459–81
- Nirogi R, Kandikere V, Mudigonda K, et al. (2010). Liquid chromatography tandem mass spectrometry method for the quantification of sarpogrelate, a selective 5-HT(2A) receptor antagonist, in plasma: application to a pre-clinical pharmacokinetic study. Biomed Chromatogr 24:1159–67
- Pertz H and Elz S. (1995). In-vitro pharmacology of sarpogrelate and the enantiomers of its major metabolite: 5-HT2A receptor specificity, stereoselectivity and modulation of ritanserin-induced depression of 5-HT contractions in rat tail artery. J Pharm Pharmacol 47:310–16
- Rashid M, Manivet P, Nishio H, et al. (2003). Identification of the binding sites and selectivity of sarpogrelate, a novel 5-HT2 antagonist, to human 5-HT2A, 5-HT2B and 5-HT2C receptor subtypes by molecular modeling. Life Sci 73:193–207
- Saini HK, Takeda N, Goyal RK, et al. (2004). Therapeutic potentials of sarpogrelate in cardiovascular disease. Cardiovasc Drug Rev 22:27–54
- Shinohara Y, Nishimaru K, Sawada T, et al.; S-ACCESS Study Group. (2008). Sarpogrelate-aspirin comparative clinical study for efficacy and safety in secondary prevention of cerebral infarction (S-ACCESS): a randomized, double-blind, aspirin-controlled trial. Stroke 39:1827–33
- Zhang C, Wang L, Yang Y, et al. (2010). Validated LC-MS/MS method for the determination of sarpogrelate in human plasma: application to a pharmacokinetic and bioequivalence study in Chinese volunteers. J Pharm Biomed Anal 53:546–51